Výsledky vyhledávání - "May Lin Helen Oh"

Akademický článek

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster

Autor: Chin Shern Lau, John Thundyil, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu, Tar Choon Aw

Publikováno v: Antibodies, Vol 11, Iss 4, p 70 (2022)

Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 B

Externí odkaz: https://doaj.org/article/6fc269d39cdf4f518c82e074b0a6b2eb

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine

Autor: Chin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, Ya-Li Liang, Tar Choon Aw

Publikováno v: Vaccines, Vol 10, Iss 10, p 1703 (2022)

Introduction: We tested the total spike antibody (S-Ab), IgG/IgM S-Ab, and neutralizing antibody (N-Ab) responses of COVID-19-naïve subjects from before their first BNT162b2 vaccination up to 210 days after boosting. Methods: We studied 136 COVID-19

Externí odkaz: https://doaj.org/article/1a52089bd11a43e2a981806ec44f4a8b

Zobrazit plný text záznamu

Akademický článek

Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore

Autor: Chin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu, Tar Choon Aw

Publikováno v: Antibodies, Vol 11, Iss 2, p 38 (2022)

Introduction: We compared the early total spike antibody (S-Ab) and neutralizing antibody (N-Ab) responses to two vaccines. Methods: We studied 96 Pfizer and 34 Sinovac vaccinees over a 14-month period from January 2021 to February 2022. All vaccinee

Externí odkaz: https://doaj.org/article/bcc81309fef449ffacfe37038d9049ef

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore

Autor: Chin Shern Lau, Soon Kieng Phua, Ya Li Liang, May Lin Helen Oh, Tar Choon Aw

Publikováno v: Vaccines, Vol 10, Iss 2, p 331 (2022)

Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore. Methods: Participants (n = 43) were tested pre-booster and 20/30/60/90 days post-booster. Participants were boosted 120–240 days (mean 214 days) after their secon

Externí odkaz: https://doaj.org/article/b81ab907db704724a572b3a4798e4791

Zobrazit plný text záznamu

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

Autor: Lynette Pei-Chi Shek, May-Lin Helen Oh, Matthew Bonaparte, Hao Wang, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon, Juliana Park, Frédérique Jantet-Blaudez, Sophia Archuleta, Alain Bouckenooghe, Carina Frago

Publikováno v: Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record

The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7676baa81ef947c4866817a6ecdc890b
http://europepmc.org/articles/PMC8189141

Zobrazit plný text záznamu

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series

Autor: Sophia Archuleta, May-Lin Helen Oh, Matthew Bonaparte, Alain Bouckenooghe, Carina Fargo, Jing Jin, Lynette Pei-Chi Shek, Juliana Park

Publikováno v: Human Vaccines & Immunotherapeutics

The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b92eb20fd746b03c8bf69d9d97d599f
https://doi.org/10.1080/21645515.2019.1661204

Zobrazit plný text záznamu

Meningococcal and Travellers' Vaccinations

Autor: May Lin Helen oh

Publikováno v: The Singapore Family Physician. 44:25-30

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::772b5daae501e11f3ee77d39bf5b99c2
https://doi.org/10.33591/sfp.44.2.u3

Zobrazit plný text záznamu

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

Autor: May Lin Helen Oh, Annelies Wilder-Smith, Alain Bouckenooghe, Hoe Nam Leong, T. Anh Wartel, Yee Sin Leo, Lynette Pei-Chi Shek, Sophia Archuleta, Chia Yin Chong, Denis Crevat, Chian Yong Low

Publikováno v: Human Vaccines & Immunotherapeutics

This was a multicenter, blinded, Phase II study (NCT00880893) conducted in Singapore. The primary objectives were to evaluate the safety of a tetravalent dengue vaccine (TDV) comprising four recombinant, live, attenuated viruses (CYD-TDV) and the den

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6261f69f1ed8d261c6e439ea6b84d5e
https://pubmed.ncbi.nlm.nih.gov/22894958

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání